PRME
PRME
NASDAQ · Biotechnology

Prime Medicine Inc

$2.98
+0.17 (+6.05%)
As of Aug 8, 1:50 AM ET ·
Analyst Consensus
Strong Buy
19
Analysts
High
Coverage
Buy 15 79%
Hold 4 21%
Sell 0 0%
Price Target
Analyst Price Target +1,349.3% upside
Low Target $33.60
Average Target $43.19
High Target $71.66
Current Price $2.98
Current
$2.98
Target
$43.19
$33.60 $43.19 avg $71.66
Scenario Analysis
Bear Case
$33.60
1,027.5%
Low target
Base Case
$43.19
+1,349.3%
Avg target
Bull Case
$71.66
+2,304.7%
High target
Risk/Reward
2.2x
Favorable
Price in Context
52-Week High
$6.94
-57.1% from high
52-Week Low
$2.67
+11.6% from low
Target vs 52W High
$43.19
+522.3% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 79% $257.58 +4.7%
AMGN
Amgen Inc
Hold 43 49% $190.87 -53.6%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +172.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -11.6%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -90.2%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -55.6%
RVMD
Revolution Medicines Inc
Strong Buy 29 93% $114.11 -44.4%
BIIB
Biogen Inc
Buy 44 64% $91.45 -56.0%